Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights

REFERENCES

• Chen JJ, Obering C. Apomorphine in the management of motor fluctuations associated with Parkinson's disease. Clin Ther. 2005;27:1710–24
   PubMed Web of Science ®Google Scholar
• Apokyn [package insert]. Brisbane, CA: Ipsen; 2010.
   Google Scholar
• Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients—a double blind study. Parkinsonism Relat Disord. 1997 Dec;3(4):191–3.
   PubMedGoogle Scholar
• Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30:287–94.
   PubMed Web of Science ®Google Scholar
• Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulmanant hepatitis. Lancet. 1998;352: 958.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch Neurol. 2000;57:263–7.
   PubMed Web of Science ®Google Scholar
• Haasio K. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol. 2010;95:163–89.
   PubMed Web of Science ®Google Scholar
• Korri H, Awada A. Serious tolpcapone-induced hepatitis 17 months after commencing treatment. Rev Neurol (Paris). 2005 Nov;161:1113–5.
   PubMedGoogle Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–10.
   PubMed Web of Science ®Google Scholar
• Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs. 2011;25:203–12.
   PubMed Web of Science ®Google Scholar
• Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr Neurol Neurosci Rep. 2006;6: 169–76.
   PubMed Web of Science ®Google Scholar
• Manni R, Terzaghi M, Sartori I, Mancini F, Pacchetti C. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. Sleep Med. 2004;5:189–93.
   PubMed Web of Science ®Google Scholar
• Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease. JAMA. 2002;287:455–63.
   PubMed Web of Science ®Google Scholar
• Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O'Sullivan JD. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction. 2010;106:283–93.
   PubMedGoogle Scholar
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson's disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–95.
   PubMed Web of Science ®Google Scholar
• Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann NY Acad Sci. 2008;1142:85–107.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Voon V, Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol. 2007;3:664–72.
   PubMedGoogle Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders—text revision (DSM-IV-TR). Washington, DC: APA; 2000.
   Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson's disease. Arch Neurol. 2006;63:969–73.
   PubMed Web of Science ®Google Scholar
• Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34:66–70.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33:81–7.
   PubMedGoogle Scholar
• Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2008;14:448–9.
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol. 2010;257:1682–5.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15(Suppl 4):S111–5.
   PubMedGoogle Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.
   PubMed Web of Science ®Google Scholar
• Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med J. 2003;96:635–42.
   Google Scholar
• Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009;11(6):353–6.
   PubMedGoogle Scholar
• Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology. 1960;10:1076078.
   Google Scholar
• Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48:1070–77.
   PubMed Web of Science ®Google Scholar
• Sanyal D, Chakraborty S, Bhattacharyya R. An interesting case of serotonin syndrome precipitated by escitalopram. Indian J Pharmacol. 2010;42:418–9.
   PubMedGoogle Scholar
• Hinds NP, Hillier CEM, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247:811.
   PubMedGoogle Scholar
• Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, Dhimes Tejada P. Serotonin syndrome: report of a fatal case and review of the literature. Rev Clin Esp. 2002;202:209–11.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol. 1997;17:66–7.
   PubMedGoogle Scholar
• http://www.pharmgkb.org/search/annotatedGene/cyp2c19 (Accessed May 23, 2011)
   Google Scholar
• Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001 Apr;21(2):161–6.
   PubMed Web of Science ®Google Scholar
• Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51:73–8.
   PubMed Web of Science ®Google Scholar
• Fernandes C, Prashanth R, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord. 2011;26:766–7.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007;29:1825–49.
   PubMed Web of Science ®Google Scholar
• Panisset M, Schwid S, Ondo W, Fitzer-Attas C, Chen JJ. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease. Mov Disord. 2007;223(Suppl 16):S104–5.
   Google Scholar
• Montgomery EB, Panisset M. Retrospective analysis of the incidence of serotonin toxicity in patients taking rasagiline and antidepressants in clinical trials. Mov Disord. 2009;24(Suppl 1):359.
   Google Scholar
• Ghosh P, Winslow J, Musleh C, Gandhy C, Bahroo L, Pagan F. The tolerability of rasagiline when used concurrently with serotonin reuptake inhibitors in Parkinson's disease: a retrospective analysis. Mov Disord. 2010;25(Suppl 2):S400.
   Google Scholar
• Chhabria N, Ghosh P, Bahroo L, Pagan F. A “real world” view of the tolerability of rasagiline with anti-depressants in Parkinson's disease: a retrospective study. Neurology. 2011;76(Suppl 4):A485–6.
   PubMedGoogle Scholar
• Panisett M, Chen JJ, Rhyee SH. Assessing the occurrence of serotonin toxicity in Parkinson's disease patients receiving rasagiline and antidepressants. Neurology. 2011;76(Suppl 4):A539.
   Google Scholar
• Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1526–32.
   PubMed Web of Science ®Google Scholar
• Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaparine with other serotoninergic drugs. Anesth Analg. 2006;103:1466–8.
   PubMed Web of Science ®Google Scholar
• Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol (Phila). 2008;46:771–3.
   PubMed Web of Science ®Google Scholar
• Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–83.
   PubMed Web of Science ®Google Scholar
• Rivers N, Horner B. Possible lethal reaction between nardil and dextromethorphan. Can Med Assoc J. 1970;103:85.
   PubMed Web of Science ®Google Scholar
• Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibibitor therapy with isocarboxazid. N Engl J Med. 1988;319:1671.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95:434–41.
   PubMed Web of Science ®Google Scholar
• Asch DA, Parker RM. The Libby Zion case: one step forward or two steps backward? N Engl J Med. 1988;318:771–5.
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991; 337(8735):246.
   PubMed Web of Science ®Google Scholar
• Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother. 2006;40:155–7.
   PubMedGoogle Scholar
• Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol. 2001;41:224–7.
   PubMedGoogle Scholar
• Reich M, Lefebvre-Kuntz D. Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report. Encephale. 2010;36(Suppl 2):D119–23.
   Google Scholar
• Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med. 2010;38:477–80.
   PubMed Web of Science ®Google Scholar
• Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth. 2008;55:521–5.
   PubMedGoogle Scholar
• Nathan, PJ. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol. 2001;15:47–54.
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Stewart JW, Quitkin FM. A possible L-deprenyl induced hypertensive reaction. J Clin Psychopharmacol. 1989;9:310–11.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Wilkinson JR. The monoamine oxidase type-B inhibitor rasagiline in the treatment of Parkinson's disease: Is tyramine a challenge? J Clin Pharmacol. 2011 May 31 (Epub ahead of print).
   Google Scholar
• Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase inhibitor type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50:1420–8.
   PubMed Web of Science ®Google Scholar
• de Marcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I; the Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716–21.
   PubMed Web of Science ®Google Scholar
• Wilkinson J, Reichwein S, Stern M. Safety and tolerability of tyramine challenge in levodopa-treated Parkinson's disease (PD) patients receiving rasagiline. Presented at American Academy of Neurology Annual Meeting; 2008 Apr 12-19; Chicago, IL.
   Google Scholar